There has been a renewed interest in assessing the DNA-damaging agent CPT for anticancer therapy in ccRCC and other solid tumors as it possesses significant HIF-1α inhibitory activity. This evidence concerns the gene HIF1A and nonpapillary renal cell carcinoma.